Long-term surveillance study of rituximab originator treated patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)
Lay Summary: What does this mean for patients? Rituximab is used to treat active disease and to prevent relapses in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Serious complications, including infections, low natural antibody levels, cancers, low white blood cell levels, heart...
Main Authors: | Uchida, L, Jones, RB, Smith, RM, Nodale, M, Bond, S, Loechel, C, King, M, Luqmani, R, Gray, D, Barrett, J, Jayne, DRW |
---|---|
Format: | Journal article |
Jezik: | English |
Izdano: |
Oxford University Press
2024
|
Podobne knjige/članki
-
Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis
od: Shah S, et al.
Izdano: (2015-08-01) -
Echocardiogram: The GPS to GPA’s Heart (Granulomatosis with Polyangiitis)
od: Manpreet K. Parmar, et al.
Izdano: (2019-01-01) -
Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis
od: Masayoshi Harigai, et al.
Izdano: (2019-05-01) -
An Unusual Presentation of Granulomatosis with Polyangiitis (GPA): Case Report
od: Sabrina Khuder, et al.
Izdano: (2023-12-01) -
Tension Pneumothorax as Initial Manifestation of Granulomatosis with Polyangiitis (GPA)
od: Rúben Reis, et al.
Izdano: (2021-02-01)